Premium
Drug–Drug Interactions of Infectious Disease Treatments in Low‐Income Countries: A Neglected Topic?
Author(s) -
McFeely Savannah J.,
Yu Jingjing,
Zhao Ping,
Hershenson Susan,
Kern Steven,
RagueneauMajlessi Isabelle,
Hartman Dan
Publication year - 2019
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.1397
Subject(s) - intensive care medicine , drug , infectious disease (medical specialty) , medicine , disease , risk analysis (engineering) , adverse effect , pharmacology , pathology
Despite recent advances in recognizing and reducing the risk of drug–drug interactions ( DDI s) in developed countries, there are still significant challenges in managing DDI s in low‐income countries ( LIC s) worldwide. In the treatment of major infectious diseases in these regions, multiple factors contribute to ineffective management of DDI s that lead to loss of efficacy or increased risk of adverse events to patients. Some of these difficulties, however, can be overcome. This review aims to evaluate the inherent complexities of DDI management in LIC s from pharmacological standpoints and illustrate the unique barriers to effective management of DDI s, such as the challenges of co‐infection and treatment settings. A better understanding of comprehensive drug‐related properties, population‐specific attributes, such as physiological changes associated with infectious diseases, and the use of modeling and simulation techniques are discussed, as they can facilitate the implementation of optimal treatments for infectious diseases at the individual patient level.